Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

LANTHEUS HOLDINGS, INC.

Parent2 subsidiariesUEI: XKLLNAJB6LJ6CAGE: 7ZG90

LANTHEUS HOLDINGS, INC. is a federal contractor, registered under UEI XKLLNAJB6LJ6 and CAGE code 7ZG90. It has been awarded $379,822 across 3,757 federal contracts. Primary work spans Pharmaceutical Preparation Manufacturing. Top awarding agencies include Department Of Veterans Affairs.

Contact Information

Registration and classification details

Registration

UEI Code

XKLLNAJB6LJ6

CAGE Code

7ZG90

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

2XMF

NAICS Codes

325412Pharmaceutical Preparation Manufacturing(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

Lanthue Holdings, Inc. operates as a specialized manufacturer within the pharmaceutical and medical chemical production sector, as indicated by its primary NAICS code 325412. The company focuses on the development and production of radiopharmaceuticals and other advanced therapeutic agents, leveragi...

Lanthue Holdings, Inc. operates as a specialized manufacturer within the pharmaceutical and medical chemical production sector, as indicated by its primary NAICS code 325412. The company focuses on the development and production of radiopharmaceuticals and other advanced therapeutic agents, leveraging precision chemistry, radiolabeling technologies, and GMP-compliant manufacturing processes. Its technical expertise includes the synthesis of complex molecular constructs, radioactive isotope handling, and closed-system aseptic processing to support diagnostic and therapeutic applications in nuclear medicine. The firm’s differentiation lies in its ability to scale small-batch, high-purity radiopharmaceutical production under stringent regulatory frameworks, ensuring consistency and safety for clinical use. No award history is available to infer specific agency relationships or contract patterns. Consequently, there is no demonstrable track record of direct engagement with federal agencies or government procurement programs based on the provided data. The company’s industry focus is centered on NAICS 325412, which encompasses the manufacturing of radiopharmaceuticals and other diagnostic imaging agents used in nuclear medicine. This vertical requires deep competency in radiochemistry, radiation safety, and FDA-regulated production protocols. Lanthue Holdings positions itself within the niche of advanced medical isotopes and targeted therapeutics, serving the clinical diagnostics and precision medicine markets through highly specialized manufacturing capabilities. As a 2L entity headquartered in North Billerica, Massachusetts, Lanthue Holdings, Inc. is structured as a small, technically focused manufacturer without public certifications. Its geographic presence is localized to its Massachusetts facility, suggesting a concentrated operational footprint aligned with biopharmaceutical innovation hubs in the Northeast. The company’s market positioning is defined by its technical specialization rather than broad government contracting experience.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Award Analytics & Distribution

Awards by Agency
Department Of Veterans Affairs$379.8K100%
Awards by NAICS
325412 - Pharmaceutical Preparation Manufacturing$379.8K100%
Awards by Agency Over Time
Awards by Place of Performance

Compete with LANTHEUS HOLDINGS, INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for LANTHEUS HOLDINGS, INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS

Open opportunities in LANTHEUS HOLDINGS, INC.'s top NAICS codes and agencies

NAICS: 325412
New
Federal
6505--2027-2028 Influenza Virus Vaccine
Solicitation # 36E79726R0035
Solicitation 36E79726R0035 is an unrestricted FAR Part 12 commercial-item procurement issued by the Department of Veterans Affairs National Acquisition Center for the supply of Influenza Virus Vaccines for the 2027-2028 season. The contract requires the delivery of trivalent or quadrivalent vaccines in pre-filled single-dose syringes with plunger and Luer lock needle attachments, provided in boxes of 10. The vaccines must be latex and preservative free, with specific FDA approval and labeling required for pediatric populations (6 to 35 months) and seniors (65 years and older). Final vaccine presentation is based on World Health Organization recommendations, with a preference for Trivalent presentations if both Trivalent and Quadrivalent options are commercially available. The award will be made on a per solicitation line item basis for the VA, Bureau of Prisons, Indian Health Service, and the Captain James A. Lovell Federal Health Care Center. Deliveries are Free On Board Destination to government facilities across the United States, Puerto Rico, and the Philippines. Most facilities require a two-part delivery schedule, with at least 50 percent of the order delivered between August 15 and September 15, 2027, and the remainder by October 15, 2027; however, the FHCC must receive 100 percent of its awarded quantity by September 15, 2027. Offerors must provide the full quantity for any line item bid, and final pricing must include the Cost Recovery Fee and Federal Excise Tax.
Nac Pharmaceuticals (36E797)

POSTED

about 9 hours ago

DEADLINE

in 15 days
View Details
NAICS: 325412
New
Federal
6505--FDG Radiopharmaceutical
Solicitation # 36C24426Q0900
Solicitation 36C24426Q0900 is a request for quotation issued by the Department of Veterans Affairs Network Contracting Office 4 to secure a Nuclear Regulatory Commission licensed vendor for the supply of Fluorodeoxyglucose (FDG) radiopharmaceuticals. These products serve as tracers for PET/CT scans to detect cancer, evaluate inflammation, and assess organ function at the Philadelphia VA Medical Center. The estimated period of performance runs from October 14, 2026, to October 13, 2031. This is a non-set-aside acquisition for commercial items, with quotes due by September 17, 2026, at 6:00 AM ET. The contractor must adhere to strict packaging and labeling standards, ensuring all shipping containers are marked as radioactive with proper exposure levels and that unit doses include precise preparation and expiration data. Additionally, the vendor must provide bar-labeled inserts compatible with the nuclear medicine information management system, assuming all costs for data migration and training if their system differs from the current Pinestar NMIS. Award will be based on a pairwise comparison of the best overall response, evaluating price, technical capability, socioeconomic considerations, and past performance from the last three years. Payments will be processed via Electronic Funds Transfer through the System for Award Management, with electronic invoicing required via the Tungsten Network.
244-NETWORK Contract Office 4 (36C244)

POSTED

about 9 hours ago

DEADLINE

in 9 days
View Details